ethyl 1-(4-methoxyphenyl)-8-nitro-4,5-dihydro-1H-benzo[g]indazole-3-carboxylate | 1273318-64-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: ethyl 1-(4-methoxyphenyl)-8-nitro-4,5-dihydro-1H-benzo[g]indazole-3-carboxylate
• CAS: 1273318-64-1
• 化学式: C₂₁H₁₉N₃O₅
• 分子量: 393.399
• InChiKey: QNUPCJWNLDAKID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.73
• 重原子数：
  29.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  96.49
• 氢给体数：
  0.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  ethyl 1-(4-methoxyphenyl)-8-nitro-4,5-dihydro-1H-benzo[g]indazole-3-carboxylate 在 氨 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 溶剂黄146 、 N,N-二异丙基乙胺 、 锌 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 8-(2,5-dichloroisonicotinamido)-1-(4-methoxyphenyl)-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide
  参考文献：
  名称：

  Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure–activity relationship

  摘要：

  Installation of sites for metabolism in the lead compound PHA-767408 was the key focus of the IKK-2 inhaled program. This paper reports our efforts to identify a novel series of aminopyridinecarboxamide-based IKK-2 inhibitors, which display low nanomolar potency against IKK-2 with long duration of action (DOA), and metabolically labile to phase I and/or phase II metabolizing enzymes with potential capability for multiple routes of clearance. Several compounds have demonstrated their potential usefulness in the treatment of asthma and chronic obstructive pulmonary disease (COPD). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.027
• 作为产物：
  描述：

  lithium 2-ethoxy-1-(7-nitro-1-oxo-3,4-dihydronaphthalen-2(1H)-ylidene)-2-oxoethan-1-olate 、 4-甲氧基苯肼盐酸盐 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以88%的产率得到ethyl 1-(4-methoxyphenyl)-8-nitro-4,5-dihydro-1H-benzo[g]indazole-3-carboxylate
  参考文献：
  名称：

  Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure–activity relationship

  摘要：

  Installation of sites for metabolism in the lead compound PHA-767408 was the key focus of the IKK-2 inhaled program. This paper reports our efforts to identify a novel series of aminopyridinecarboxamide-based IKK-2 inhibitors, which display low nanomolar potency against IKK-2 with long duration of action (DOA), and metabolically labile to phase I and/or phase II metabolizing enzymes with potential capability for multiple routes of clearance. Several compounds have demonstrated their potential usefulness in the treatment of asthma and chronic obstructive pulmonary disease (COPD). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.027